Vedolizumab Experience in Children and Adolescents with Inflammatory Bowel Disease: A Multicenter Observational Study

Temara M. Hajjat*, Maua Mosha, Kaitlin G. Whaley, Michael J. Rosen, Carmine Suppa, James Markowitz, Lauren Dufour, Cary Sauer, Monica Shukla-Udawatta, Brendan Boyle, Meghan Gibson, Jason Shapiro, Derica Sams, Francisco Sylvester, Gabriele Hunter, Maria E. Perez, Jeffrey S. Hyams

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Background: Vedolizumab is increasingly used off-label to treat children and adolescents with inflammatory bowel disease (IBD). In the absence of rigorous clinical trial experience, multicenter observational data are important to establish expectations for efficacy and safety. We examined 1-year outcomes following vedolizumab therapy in a large multicenter pediatric IBD cohort. Methods: We performed a retrospective study of 159 pediatric patients (4-17 years old) with IBD [78, Crohn disease (CD); 81, ulcerative colitis/IBD-unspecified (UC/IBD-U)] treated with vedolizumab for 1 year at 8 pediatric medical centers in the United States. Demographics, clinical outcomes, laboratory data, and vedolizumab dosing were recorded. The primary outcome was corticosteroid (CS)-free clinical remission at 1 year. Other measured outcomes were clinical remission at 12 and/or 24 weeks, laboratory outcomes at 1 year, and endoscopy/histology results at 1 year. Results: Among the 159 patients (mean age, 14.5 ± 2.4 years; 86% anti-TNF experienced), 68/159 (43%) achieved CS-free clinical remission at 1 year (CD, 35/78, 45%; UC/IBD-U, 33/81, 40%). Vedolizumab therapy failed and was discontinued in 33/159 (21%) patients prior to 1 year (CD, 18/78, 23%; UC/IBD-U, 15/81, 19%). While week 12 clinical remission was not predictive of 1-year clinical remission in either CD or UC/IBD-U, week 24 clinical remission was predictive of 1-year clinical remission only in CD patients. No infusion reactions or serious side effects were noted. Conclusions: Vedolizumab was safe and effective in this pediatric population with approximately 43% achieving CS-free clinical remission at 1 year. Similar efficacy was noted in both CD and UC.

Original languageEnglish (US)
Article numberotab039
JournalCrohn's and Colitis 360
Issue number3
StatePublished - Jul 1 2021


  • biologic therapy
  • pediatric IBD
  • vedolizumab

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Vedolizumab Experience in Children and Adolescents with Inflammatory Bowel Disease: A Multicenter Observational Study'. Together they form a unique fingerprint.

Cite this